((自动化翻译由路透提供,请见免责声明 ))
10月28日 - ** 药物开发商 Monte Rosa Therapeutics 股价上涨 37.22% 至 6.84 美元 * (link) * 诺华 将向 GLUE 支付 1.5 亿美元的预付款,以获得开发、生产和销售某些候选药物的全球许可。
** GLUE 还将有资格获得未来高达 21 亿美元的开发、监管和销售里程碑付款
** 该协议有望加速 MRT-6160 的开发,MRT-6160 正处于免疫介导疾病的早期研究阶段。
** GLUE 的股价今年以来上涨了约 20
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.